Teicoplanin is a glycopeptide antibiotic that has no gram-negative activity and is used to treat serious staphylococcal and streptococcal infections. When compared to vancomycin, it has the advantage of requiring less frequent monitoring and is also less nephrotoxic. Because it is a big molecule, it may not always permeate specific organs (e.g., the lungs and peritoneal fluid) and should only be used when other more effective medicines, such as flucloxacillin, are unavailable. Glycopeptide-resistant enterococci may arise as a result of excessive usage (GRE). Teicoplanin belongs to the ‘glycopeptide' class of antibiotics, which kills bacteria by preventing them from building the bacterial protective wall that is needed for them to survive.
This growth is primarily driven by Increasing Prevalence of Bacterial Infection.
Globally, a noticeable market trend is evident Rising Demand for Teicoplanin as a suitable alternative to vancomycin. Major Players, such as Sanofi (France), Labatec-Pharma SA (Switzerland), Cipla (India), Zhejiang Medicine Co. Ltd. (China), ZHEJIANG HISUN PHARMACEUTICAL (China), Shiono Chemical (Japan), CKD BiO (South Korea), Zhejiang medicine (China), Huadong Medicine Co.,Ltd (China) and Biosans Lifecare (India) etc have either set up their manufacturing facilities or are planning to start new provision in the dominated region in the upcoming years.
In order to address the disharmony across the EU in terms of the requirements for generics of teicoplanin, a procedure according to Article 5(3) of Regulation EC (No) 726/2004 was triggered by France on 22 September 2011. The aim of this procedure was to achieve a consensual view of the requirements to be fulfilled to show equivalence between the generics and the reference product of this antibiotic.
- Increasing Prevalence of Bacterial Infection
- Rising Demand for Teicoplanin as a suitable alternative to vancomycin
Rising Investment from Government in R&D and Teicoplanin Administration Gains Popularity with Clinicians Dealing With TDM
Hypersensitivity reactions (including rash, bronchospasm and fever) Can Occur
AMA Research follow a focused and realistic research framework that provides the ability to study the crucial market dynamics in several regions across the world. Moreover, an in-depth assessment is mostly conducted by our analysts on geographical regions to provide clients and businesses the opportunity to dominate in niche markets and expand in emerging markets across the globe. This market research study also showcase the spontaneously changing Players landscape impacting the growth of the market. Furthermore, our market researchers extensively analyse the products and services offered by multiple players competing to increase their market share and presence.
Customization in the Report
AMA Research features not only specific market forecasts, but also include significant value-added commentary on:
- Market Trends
- Technological Trends and Innovations
- Market Maturity Indicators
- Growth Drivers and Constraints
- New Entrants into the Market & Entry/Exit Barriers
- To Seize Powerful Market Opportunities
- Identify Key Business Segments, Market Proposition & Gap Analysis
Against this Challenging Backdrop, Teicoplanin Study Sheds Light on
The Teicoplanin Market status quo and key characteristics. To end this, Analyst at AMA organize and took survey of the Teicoplanin industry Players. The resultant snapshot serves as a basis for understanding why and how the industry can be expected to change.
Where Teicoplanin industry is heading and what are the top priorities. Insights are drawn from financial analysis, the survey and interviews with key executives and industry experts.
How every company in this diverse set of Players can best navigate the emerging competition landscape and follow a strategy that helps them position to hold value they currently claim, or capture the new addressable opportunity.
Frequently Asked Questions (FAQ):1. What is the growth rate predicted for the Global Teicoplanin Market?
The Teicoplanin market is expected to see a CAGR of % during projected year 2020 to 2026.
2. Who are the top performing companies in Teicoplanin Market?
Top performing companies in the Global Teicoplanin market are Sanofi (France), Labatec-Pharma SA (Switzerland), Cipla (India), Zhejiang Medicine Co. Ltd. (China), ZHEJIANG HISUN PHARMACEUTICAL (China), Shiono Chemical (Japan), CKD BiO (South Korea), Zhejiang medicine (China), Huadong Medicine Co.,Ltd (China) and Biosans Lifecare (India), to name a few.
3. Which region dominated the worldwide market for Teicoplanin in 2020?
is dominating the Teicoplanin Market.